Iceland vs Isle of Man: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Iceland
0.0%
in 2024
Isle of Man
0.0%
in 2024
Iceland rank
167th
Isle of Man rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Iceland
- Isle of Man
How they compare
Iceland currently reports 0.0% against 0.0% in Isle of Man, a difference of 0.0%.
Across all 10 years both countries report, Isle of Man has been ahead every year.
Iceland ranks 167th and Isle of Man ranks 167th of 246 countries.
Head to head by decade
| Decade | Iceland | Isle of Man | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | — |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Iceland or Isle of Man?
- Iceland, at 0.0% against 0.0% in Isle of Man as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Iceland and Isle of Man?
- 0.0%, with Iceland ahead.
- How many years of comparable data are there for Iceland and Isle of Man?
- 10 years are reported by both, from 2015 to 2024.
- How do Iceland and Isle of Man rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Iceland ranks 167th and Isle of Man ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.